StimLabs Awarded Regenerative Biologics Contract with Vizient®

Secures access to over 3,500 U.S. Hospitals including 97% of Academic Medical Centers

ROSWELL, Ga., Aug. 4, 2025 /PRNewswire/ -- StimLabs, a pioneering regenerative science company, has been awarded a national contract for Regenerative Biologics with Vizient effective August 1, 2025. The new agreement allows Vizient's extensive network of member hospitals to take advantage of special pricing and pre-negotiated terms for StimLabs' unique portfolio of human placental membrane grafts and its cord-derived particulate device.

John Daniel, Founder and CEO at StimLabs, highlighted the importance of the contract, stating, "Our purpose has always been to transform lives through regenerative science. With this agreement we have significantly expanded our reach and are well positioned to have a larger impact on patient care at the hospital site of service."

StimLabs remains at the forefront of innovation. From its commercialization of the first-ever full thickness, intact placental membrane allograft developed with the Clearify^® technology in 2016, to its introduction of the first and only FDA 510(k)-cleared umbilical cord-derived medical device with Corplex P^® in 2024, StimLabs has consistently set the standard for excellence in the market.

"We continue to execute on our strategy to strengthen our presence in the acute care space and our agreement with Vizient is another important milestone. With this agreement we have secured access to over 65% of the nation's acute care providers, furthering our ability to serve more patients with our diverse portfolio, including our latest innovation Corplex P," stated Tom Dion, Executive VP and Chief Commercial Officer.

ABOUT STIMLABS

StimLabs LLC was founded in 2015 with the mission to innovate with purpose to transform lives through regenerative science. Comprised of industry leaders, StimLabs is dedicated to offering patients the best possible care while recognizing the urgency of providing solutions in areas with unmet needs. StimLabs has a comprehensive product portfolio addressing various clinical applications and has established a strong intellectual property catalog. Committed to delivering superior products, StimLabs is a trusted partner to physicians and patients alike.

For more information, visit www.stimlabs.com.

ABOUT VIZIENT

Vizient provides network-powered insights in the critical areas of clinical, operational and supply chain performance and empowers clients to deliver exceptional, cost-effective care.

Media Contact: [email protected], (470) 616-0958

View original content to download multimedia:https://www.prnewswire.com/news-releases/stimlabs-awarded-regenerative-biologics-contract-with-vizient-302520365.html

SOURCE StimLabs